Abstract
Global Polio Eradication began in 1988, with a time target of 2000, but it remains unfinished in 2023. Since 2000, polio caused by vaccine-virus-turned wild-like has been paralyzing many children in several countries that still use the live attenuated oral polio vaccine (OPV), according to the policy of Global Polio Eradication Initiative (GPEI). We have detected a fundamental flaw in GPEI’s intervention tactics that began in 1988 with the exclusive use of OPV – which contravened the principles of medical ethics, namely beneficence, non-maleficence and justice – while a safe and highly efficacious alternative, the inactivated poliovirus vaccine (IPV), was already available. This flaw remained unrecognized as the common perception is that public health actions are ‘public good,’ hence outside the purview of medical ethics. We argue why medical ethics must apply to public health when a pharmaceutical substance is included in the intervention. Having identified unethical vaccine-choice as the root cause of both the failure to eradicate polio so far and causing widespread iatrogenic polio, it is imperative that the flawed policy is reversed at the earliest, for which we propose a way forward. We also advocate for financial compensation to be given to all individuals harmed by the unethical vaccine-policy of GPEI.
Reference56 articles.
1. Beauchamp EL, Childress JF. Principles of Biomedical Ethics. Second Edition. New York: Oxford University Press;1983.
2. Sampath R. When is iatrogenic harm negligent? AMA J Ethics 2022; 24(8): E735-739. DOI 10.1001/amajethics.2022.735.
3. American Medical Association. Council on Ethical and Judicial Affairs. Competence, self-assessment and self-awareness. Report 1-I-19. Available at https://www.ama-assn.org/system/files/2019-12/i19-ceja-report-1.pdf.
4. Twerski A, Cohen NB. Informed decision-making and the law of torts: the myth of justiciable causation. U Ill L Rev 1988; 607-665.
5. Idanpaan-Heikkila. WHO guidelines for good clinical practice (GCP) for trials in pharmaceutical products: responsibilities of the investigator. Ann Med 1994; 26(2):89-94. doi: 10.3109/07853899409147334
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献